Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years
BACKGROUND: Recently, many broadly applicable and potent neutralizing antibodies have been screened from HIV-1-infected patients. However, all these effective neutralizing antibodies were isolated from patients naive to anti-retroviral treatment (ART).
METHODS: To better understand the induction of neutralizing antibodies in patients on ART, we screened 3 patients with an over ten-year infection history on ART from 350 patients in China for a cross-reactive neutralizing antibody response based on the use of different antigens and recombinant viruses. We studied the evolution of neutralizing activity in two patients during a one-year period with previously described recombinant viruses NL4-3 and SF162 using ELISA and neutralization assays.
RESULTS: Antibodies purified from sera were able to react with recombinant virus antigens R2-gp120 and SF162-gp140 and neutralize SF162 recombinant virus but not NL4-3 recombinant virus. In addition, we observed a significant increase in the neutralizing response of immunoglobulin G (IgG) isolated from the serum sample in Patient 1 and compared it with the serum from Patient 1 six months ago.
CONCLUSIONS: We thus confirm the possibility of production of neutralizing antibodies in patients infected for over ten years on ART, and it is possible over time of the improvement of HIV-1 potent neutralizing activity associated with viremia and immune reconstruction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Clinical laboratory - 65(2019), 7 vom: 01. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Weiyou [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.01.2020 Date Revised 06.01.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7754/Clin.Lab.2019.181240 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29920118X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29920118X | ||
| 003 | DE-627 | ||
| 005 | 20231225095826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7754/Clin.Lab.2019.181240 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM29920118X | ||
| 035 | |a (NLM)31307159 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Weiyou |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2020 | ||
| 500 | |a Date Revised 06.01.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Recently, many broadly applicable and potent neutralizing antibodies have been screened from HIV-1-infected patients. However, all these effective neutralizing antibodies were isolated from patients naive to anti-retroviral treatment (ART) | ||
| 520 | |a METHODS: To better understand the induction of neutralizing antibodies in patients on ART, we screened 3 patients with an over ten-year infection history on ART from 350 patients in China for a cross-reactive neutralizing antibody response based on the use of different antigens and recombinant viruses. We studied the evolution of neutralizing activity in two patients during a one-year period with previously described recombinant viruses NL4-3 and SF162 using ELISA and neutralization assays | ||
| 520 | |a RESULTS: Antibodies purified from sera were able to react with recombinant virus antigens R2-gp120 and SF162-gp140 and neutralize SF162 recombinant virus but not NL4-3 recombinant virus. In addition, we observed a significant increase in the neutralizing response of immunoglobulin G (IgG) isolated from the serum sample in Patient 1 and compared it with the serum from Patient 1 six months ago | ||
| 520 | |a CONCLUSIONS: We thus confirm the possibility of production of neutralizing antibodies in patients infected for over ten years on ART, and it is possible over time of the improvement of HIV-1 potent neutralizing activity associated with viremia and immune reconstruction | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a HIV Antibodies |2 NLM | |
| 650 | 7 | |a HIV Envelope Protein gp120 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a env Gene Products, Human Immunodeficiency Virus |2 NLM | |
| 650 | 7 | |a gp140 envelope protein, Human immunodeficiency virus 1 |2 NLM | |
| 700 | 1 | |a Wang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Boqing |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Zhenzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Huilin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanli |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Yuanyuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical laboratory |d 1998 |g 65(2019), 7 vom: 01. Juli |w (DE-627)NLM096449845 |x 1433-6510 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2019 |g number:7 |g day:01 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7754/Clin.Lab.2019.181240 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2019 |e 7 |b 01 |c 07 | ||